Efficacy of intravitreal bevacizumab in treatment of proliferative type 2 idiopathic juxtafoveal telangiectasia

4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Objectives: To evaluate the effectiveness of intravitreal bevacizumab (IVB) in patients with subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia. Materials and Methods: Ten eyes of 10 patients were included in this retrospective study. All cases were treated with IVB (1.25 mg bevacizumab). Visual acuity and slit-lamp anterior and posterior segment examinations were performed at each visit. Central macular thickness (CMT) and intraretinal/subretinal fluid were evaluated via spectral domain optical coherence tomography (OCT). Loss of a line in visual acuity chart and presence of fluid on OCT were defined as criteria for repeated treatment. Results: The mean age of patients was 66.0±7.0 years (56-75). The mean follow-up time was 54.7±16.0 month (24-72). The mean BCVA was 0.62±0.35 (0.00-1.00) logMAR at baseline and 0.54±0.35 (0.00-1.00) logMAR at final exam (p=0.03). The mean CMT was 251±25.4 µm at baseline and 239±39.3 µm at final exam (p=0.01). Patients received an average of 1.7±1.0 IVB injections during follow-up. At baseline, all cases had intraretinal/subretinal fluid. There was no fluid at final examination of all cases. Conclusion: IVB treatment may be effective in the treatment of subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia.

Cite

CITATION STYLE

APA

Baz, Ö., Yılmaz, İ., Alagöz, C., Demircan, A., Perente, İ., Özkaya, A., & Taşkapılı, M. (2017). Efficacy of intravitreal bevacizumab in treatment of proliferative type 2 idiopathic juxtafoveal telangiectasia. Turk Oftalmoloiji Dergisi, 47(3), 144–148. https://doi.org/10.4274/tjo.04874

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free